Table 2 Comparison of clinical outcomes by patent ductus arteriosus (PDA) treatment status
Treated PDA (n = 261) | No treatment of PDA (n = 345) | p-value* | |
|---|---|---|---|
BPD n (%) | 210 (80.5) | 183 (53.0) | < 0.0001 |
Necrotizing enterocolitis (Bells stage 2a or higher) n (%) | 29 (11.1) | 22 (6.4) | 0.04 |
PDA treated medically n (%) | 168 (64.4) | - | - |
PDA treated surgically n (%) | 12 (4.6) | - | |
PDA treated both medically and surgically n (%) | 57 (21.8) | - | |
Treatment unknown n (%) | 24 (9.2) | - | |
Vasopressor Medications n (%) | |||
None | 150 (57.5) | 245 (71.0) | 0.02 |
Vasopressors alone | 45 (17.2) | 45 (13.0) | |
Vasopressors + hydrocortisone | 66 (25.3) | 55 (15.9) | |
Severe Sepsis n (%) | 24 (9.2) | 15 (4.3) | 0.02 |
Severe IVH n (%) | 36 (13.8) | 37 (10.7) | 0.25 |
Nephrotoxic Medications n (%) | |||
Indomethacin | 172 (65.9) | 116 (33.6) | < 0.0001 |
0–3 DOL | 68 (26.1) | 114 (33.0) | 0.06 |
4 + DOL | 140 (53.6) | 4 (1.2) | < 0.0001 |